Skip to main navigation

Skip to content

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

About Us
Investors
Pipeline
Clinical Trials
- Clinical Trials
- Resources
Conversations
We're Hiring

Press Releases

Press Releases
Events & Presentations

2023
2022
2021
2020
2019

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

May 23, 2023

Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

May 18, 2023

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 04, 2023

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

May 01, 2023

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

Apr 19, 2023

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

Apr 12, 2023

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

Mar 28, 2023

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

Mar 27, 2023

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

Mar 23, 2023

Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

Mar 21, 2023

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

Mar 16, 2023

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

Mar 15, 2023

Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

Mar 07, 2023

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

Feb 22, 2023

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia

Feb 21, 2023

Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

Feb 09, 2023

Terms of Use FCOI Policy Privacy Policy Contact us

Copyright© 2023 Cognition Therapeutics, Inc. All rights reserved